Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.36 |
| ▸ | PIM1 | P11309 | 9/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 9/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12078550 | 0.88 | PIM2 (0.35) | ERN1PIM2PIM1PIM3MAPT | |
| SCHEMBL1711596 | 0.82 | PIM1 (0.44) | PIM2PIM1PIM3MAPTMAPK1 | |
| SCHEMBL320431 | 0.81 | MAPT (0.37) | PIM2PIM1PIM3MAPTMAPK1 | |
| SCHEMBL29599827 | 0.81 | PIM2 (0.46) | PIM2PIM1PIM3MAPTMAPK1 | |
| SCHEMBL15872950 | 0.81 | PIM2 (0.46) | PIM2PIM1PIM3MAPTMAPK1 | |
| SCHEMBL29600679 | 0.80 | MAPT (0.47) | PIM2PIM1PIM3MAPTGSK3B | |
| SCHEMBL15872828 | 0.80 | MAPT (0.47) | PIM2PIM1PIM3MAPTGSK3B | |
| SCHEMBL12078471 | 0.80 | ALDH1A1 (0.40) | ERN1PIM2PIM1PIM3MAPT | |
| SCHEMBL319384 | 0.78 | IAPP (0.46) | PIM2PIM1PIM3MAPTALDH1A1 | |
| SCHEMBL319082 | 0.78 | GAA (0.38) | PIM2PIM1PIM3MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681195-A1 | NOVEL KINASE INHIBITORS | Novartis AG (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-2590968-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| WO-2012120428-A1 | NOVEL KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012120428-A1 | NOVEL KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | PIM1, PIM2, PIM3 | ERN1 394/4885PIM2 2/4885PIM1 1/4885 |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | PIM1, GSK3A, GSK3B | ERN1 778/4885PIM2 4/4885PIM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.